N/A N=103 USS Training to Improve Social Function in People With Psychosis
Psychosis
Primary: Social Functioning Scale (SFS) Change — 1.28; 0.19; 1.56; 0.32 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=15 A Non-invasive Intervention (BreEStim) for Management of Phantom Limb Pain (PLP) After Limb Amputation (Experiment 1)
Pain Management
Primary: Change in Pain Level as Measured by the Visual Analog Scale (VAS). — 1.38; 1.27 score on a scale
Phase 2 N=191 A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis
Myelofibrosis (MF)
Primary: Percentage of Participants With ≥ 35% Reduction From Baseline in Spleen Volume at Week 24 — 26.47; 21.98; 11.76; 62.50 percentage of participants
N/A N=1,681 Text Message Quit Vaping Intervention for Adolescents
Vaping · Cessation, Tobacco
Primary: Self-reported 30-day Point Prevalence Abstinence — 287; 208; 49 Participants
N/A N=26 Intensive TMS for Bipolar Depression
Bipolar Depression · Treatment Resistant Depression
Primary: Clinical Efficacy of High Dose Spaced Theta Burst (HDS-TBS) — 30.4; 28; 10.5; 25.3 score on a scale — p=<0.001
Phase 2 N=32 Ixazomib Rollover Study
Multiple Myeloma · Lymphoma · Amyloidosis
Primary: Number of Participants With Serious Adverse Events (SAEs) — 12; 4 Participants
N/A N=64 SpO2 Data Collection in Pediatric Patients Using INVSENSOR00061
Spo2
Primary: SpO2 Accuracy of INVSENSOR00061 — 0.87 percent of oxygen saturated hemoglobin
N/A N=450 Biomarkers of Exposure and Biomarkers of Potential Harm in Adult Smokers Who Completely Switch to E-vapor Products
Tobacco Use
Primary: Summary of Urine Total NNAL and Absolute Change From Baseline (ng/g) by Study Group and Visit From Week 1 to Week 12 (mITT Population) [ALCS-RA-16-06-EV] — 309.098…
Phase 3 N=499 PRidopidine's Outcome On Function in Huntington Disease, PROOF- HD
Huntington Disease
Primary: Change From Baseline in the Unified Huntington Disease Rating Scale-Total Functional Capacity (UHDRS-TFC) Score (mITT) — -1.18; -0.95 score on a scale — p=0.1670
Phase 3 N=190 Study of Diagnostic Performance of [18F]CTT1057 in BCR
Prostatic Neoplasms · Prostate Cancer · Recurrence
Primary: Region-level Correct Localization Rate (CLR) of Vidoflufolastat (18F) — 75.0; 68.9; 65.2 Percentage of regions
N/A N=375 Contingency Management to Enhance Office-Based Buprenorphine Treatment
Opioid-use Disorder
Primary: Buprenorphine Adherence as Assessed by the Percentage of Buprenorphine-positive Urine Samples — 80; 84; 78 percentage of urine samples — p==0.22
Phase 2 N=53 Pertussis Challenge Study in Adults Vaccinated With BPZE1
Pertussis/Whooping Cough · Bordetella Pertussis, Whooping Cough
Primary: Number of Participants Colonized Following Virulent Challenge — 8; 12 Participants
N/A N=60 mHealth Technologies to Enhance PrEP Adherence Among Thai MSM
Adherence, Patient · Pre-Exposure Prophylaxis · HIV/AIDS
Primary: Intervention Feasibility: Average Number of Days of Any App Use — 68 days
N/A N=1,516 Brain Injury Rehabilitation Improving the Transition Experience
Traumatic Brain Injury
Primary: Participation Assessment With Recombined Tools - Objective 17 (PART-O-17) — 1.30; 1.33 units on a scale — p=0.44
N/A N=86 HRIPT for Collagen Dressing
Skin Sensitisation
Primary: Skin Sensitization Reaction Using Berger and Bowman Scale — 0; 0; 0; 0 score on a scale